ライフサイエンスコーパス: ventricular failure

1 , renal replacement therapy, or severe right ventricular failure.

2 can progress and result in progressive right ventricular failure.

3 dial infarction, Q wave infarction, and left-ventricular failure.

4 t were not associated with clinical systemic ventricular failure.

5 -expressing mice, even prior to the onset of ventricular failure.

6 e animals that received L-NAME died of right ventricular failure.

7 tive heart failure died from refractory left ventricular failure.

8 was used as a molecular phenotypic marker of ventricular failure.

9 ancy with the development of angina and left ventricular failure.

10 elated mortality associated with acute right ventricular failure.

11 mally elevated pulmonary pressures and right ventricular failure.

12 ular tachycardia, and (5) treatment of right ventricular failure.

13 unloading, protection of kidneys, and right ventricular failure.

14 and early mortality due to systemic (right) ventricular failure.

15 ed, in contrast to what is described in left ventricular failure.

16 ascular resistance and, eventually, in right ventricular failure.

17 ling of the pulmonary vasculature, and right ventricular failure.

18 eath contributing to the progression of left ventricular failure.

19 artery pressure, often culminating in right ventricular failure.

20 t ventricular dysfunction and nine had right ventricular failure.

21 sfunction, pulmonary hypertension, and right ventricular failure.

22 ysiology, assessment and management of right ventricular failure.

23 es for the diagnosis and management of right ventricular failure.

24 ublished practice guideline focused on right ventricular failure.

25 ute pulmonary vascular dysfunction and right ventricular failure.

26 to extensive left ventricular infarction and ventricular failure.

27 othoracic surgery, require therapy for right ventricular failure.

28 tients with pulmonary hypertension and right ventricular failure.

29 complicated by cardiogenic shock due to left ventricular failure.

30 death has been questioned as a mechanism of ventricular failure.

31 or beta(1)AR have resulted in phenotypes of ventricular failure.

32 R with 884 patients who had predominant left ventricular failure.

33 on results in bradycardia and development of ventricular failure.

34 ction than patients under 60 years with left-ventricular failure.

35 Among 3923 patients with CS due to ventricular failure (32% female), 1235 (31%) had CS afte

36 Predominant left ventricular failure (78.5%) was most common, with isolat

37 ght atrial pressure, is a predictor of right ventricular failure after inferior myocardial infarction

38 Right ventricular failure after LVAD surgery is associated wit

39 ry hypertension, which can progress to right ventricular failure, an important cause of morbidity and

40 survival was 90% for septic shock with left ventricular failure and 64.7% in patients with distribut

41 nd banding of ascending aorta producing left ventricular failure and cardiogenic shock.

42 wave reflections in the pathogenesis of left ventricular failure and cardiovascular disease, but thei

43 iver transplantation (OLT) may develop right ventricular failure and death.

44 ry arterial pressure, often leading to right ventricular failure and death.

45 tion of pulmonary vascular resistance, right ventricular failure and death.

46 ary perfusion, ultimately resulting in right ventricular failure and dilation.

47 trials: the Prospective Randomized study Of Ventricular failure and Efficacy of Digoxin (PROVED) and

48 antially affected by the development of left-ventricular failure and other clinical indices, such tha

49 a higher incidence of post-transplant right ventricular failure and overall mortality (P<0.05).

50 size and pressure, and likely reflect right ventricular failure and overload.

51 transplant recipients who suffer from right ventricular failure and rejection and may undergo repeat

52 e characterized by increased pressure, right ventricular failure, and death.

53 es, leading to pulmonary hypertension, right ventricular failure, and death.

54 pulmonary arterial hypertension (PAH), right ventricular failure, and death.

55 ry arterioles, pulmonary hypertension, right ventricular failure, and death.

56 o elevated pulmonary-artery pressures, right-ventricular failure, and death.

57 increased pulmonary artery pressures, right ventricular failure, and death.

58 ely to develop complications related to left ventricular failure, and have improved early and late su

59 sulting in systemic hypertension, acute left ventricular failure, and multiple cardiac arrhythmias al

60 Acute right ventricular failure (ARVF) is commonly seen in the inten

61 in their practice, but until recently right ventricular failure as a primary clinical entity receive

62 ently elevated in patients with chronic left ventricular failure as a result of dysregulation of vasc

63 pression of Galphaq develop progressive left ventricular failure associated with myocyte contractile

64 eta-blockers in patients with isolated right ventricular failure because of pulmonary arterial hypert

65 rative period were not attributable to right ventricular failure (chronic thromboembolic pulmonary hy

66 se, with higher rates of both for those with ventricular failure, compared with patients who had mech

67 Patients with shock due to left ventricular failure complicating myocardial infarction w

68 ing, infection, neurologic events, and right ventricular failure continue to limit broader implementa

69 can develop cardiovascular injury including ventricular failure, coronary artery aneurysms, or shock

70 of the Glenn or Fontan procedure, including ventricular failure, cyanosis, protein-losing enteropath

71 hat in atrial myocytes from hearts with left ventricular failure, enhanced CaTs during ECC exert posi

72 reful perioperative attention to avoid right ventricular failure from acutely elevated pulmonary arte

73 Right ventricular failure from increased pulmonary vascular lo

74 Patients with CS caused by ventricular failure had more severe atherosclerosis, and

75 Patients aged 70 years or older without left-ventricular failure had significantly better survival at

76 tients who underwent angiography, those with ventricular failure had significantly lower in-hospital

77 rstanding of the mechanisms underlying right ventricular failure has improved.

78 es of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly underst

79 ogressive SAVV regurgitation causes systemic ventricular failure in CCTGA patients, who are commonly

80 In addition, Poly(I:C) also reduced right ventricular failure in established pulmonary hypertensio

81 rious side effects were exacerbation of left ventricular failure in patients with congestive heart fa

82 if patient survival and mechanisms of right ventricular failure in pulmonary hypertension could be p

83 focus on the pathophysiology of acute right ventricular failure in the critical care setting and sum

84 tion progresses to congestive left and right ventricular failure in the KO hearts.

85 ith low oxygen saturation; treatment of left ventricular failure in those with postcapillary pulmonar

86 ost common serious adverse events were right ventricular failure (in 3% of patients in each group) an

87 Importantly, for patients with ventricular failure, in-hospital mortality also correlat

88 n was associated with hemodynamic changes of ventricular failure including lower resting ejection fra

89 Acute right ventricular failure is a complex and rapidly progressive

90 Right ventricular failure is a major predictor for patients su

91 ccur, nor are there values below which right ventricular failure is always avoidable.

92 Left ventricular failure is associated with a decrease of myo

93 ble hemodynamic threshold beyond which right ventricular failure is certain to occur, nor are there v

94 Left ventricular failure is commonly preceded by a period of

95 Right ventricular failure is usually due to a combination of r

96 discusses the pathophysiology of acute right ventricular failure, its differential aetiologies, clini

97 rial Registry patients with predominant left ventricular failure (LVF) were divided into four groups:

98 Right ventricular failure may be defined as the inability of t

99 ics, critical illness, intensive care, right ventricular failure, mitral stenosis, prostacyclin, nitr

100 ased pulmonary vascular resistance and right ventricular failure; morbidity and mortality remain unac

101 Right ventricular failure occurred in one third of patients an

102 cohort died of their disease; however, right ventricular failure or sudden death was the sole cause o

103 ted individuals are at risk of left or right ventricular failure, or both.

104 e cardiogenic shock is due primarily to left ventricular failure, other causes such as acute mitral r

105 post-heart transplantation in 22, and right ventricular failure post-implantable left VAD in 13.

106 Right ventricular failure predicts early mortality in patients

107 Additional right ventricular failure predisposed to futility (hazard rati

108 It is usually seen as a consequence of left ventricular failure, pulmonary embolism, pulmonary hyper

109 sing the search words right ventricle, right ventricular failure, pulmonary hypertension, sepsis, sho

110 Primary left ventricular failure resulting in death occurred in 2 pat

111 egarding the optimal method to predict right ventricular failure resurface, along with a modern armam

112 : age over 65 years, hypertension, diabetes, ventricular failure, rheumatic valvular disease, and pri

113 ratio>0.6) of whom four patients had a right ventricular failure (right ventricular end-diastolic are

114 Critical care specialists encounter right ventricular failure routinely in their practice, but unt

115 ikelihood of developing post-operative right ventricular failure (RV failure) in the setting of mecha

116 The existing models predicting right ventricular failure (RVF) after durable left ventricular

117 re Risk Score was developed to predict right ventricular failure (RVF) after left ventricular assist

118 To review recent insights on right-ventricular failure (RVF) following left-ventricular ass

119 OF REVIEW: Pulmonary hypertension and right ventricular failure (RVF) in left ventricular systolic d

120 Right ventricular failure (RVF) in pulmonary hypertension (PH)

121 Right ventricular failure (RVF) is a cause of major morbidity

122 Right ventricular failure (RVF) is a leading driver of morbidi

123 sion (PAH) often results in death from right ventricular failure (RVF).

124 rowth hormone administered to rats with left ventricular failure starting 1 month after MI was associ

125 al work elucidating the pathobiology of left ventricular failure, there is a paucity of data on the c

126 and keywords associated with heart failure, ventricular failure, ventricular dysfunction, and cardia

127 overall and by shock etiology: left or right ventricular failure versus mechanical complications.

128 Right ventricular failure was defined as the need for post-ope

129 The severity of PAH and right ventricular failure was similar between those with and w

130 Left ventricular failure was the most common cause of death (

131 Left ventricular failure was the most frequent cause of CS fo

132 Left-ventricular failure was the strongest independent predic

133 Perioperative right ventricular failure was treated in most patients with in

134 Clinical systemic ventricular failure was uncommon, and at last follow-up,

135 ients with mechanical complications or right ventricular failure were excluded.

136 tanding of the molecular mechanisms of right ventricular failure will lead to the development of new

137 h sudden cardiovascular collapse, acute left ventricular failure with pulmonary edema, disseminated i

138 pulmonary arteries, often resulting in right ventricular failure with shortness of breath and syncope

139 except in cases of early perioperative right ventricular failure, with no deaths.